Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL22P CAR-T/CAR-TILs in Advanced Solid Tumors
NCT04556669Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Aug 2020
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SL22P in solid tumor, Cervical Cancer (CC), sarcoma and 1 more, sponsored by Senlang Bio. Primary endpoint: Safety evaluation at 3 months. Status: unknown.
02
Drugs
SL22P
03
Conditions
solid tumorCervical Cancer (CC)sarcomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04556669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556669.